Joint venture takes Profile towards US presence

- Last updated on GMT

Related tags: Joint venture, Asthma

A joint venture between UK inhaler specialist Profile and generics
company Breath opens up a new market valued at $1 billion

Profile Therapeutics has formalised a joint venture with Breath Ltd that opens the door to the roll out of its drug delivery technologies in North America.

The deal focuses on the development of a range of added-value respiratory drugs based on generic compounds supplied by Breath and Profile's Miniature Intelligent Inhalation system.

MIA comes under the banner of Profile's Adaptive Aerosol Delivery inhaler systems, that automatically respond to individual patients' breathing patterns to deliver a precise dose and have been shown under long-term clinical trials to significantly enhance patient compliance to therapy.

The first drug formats to be marketed will include the mainstay treatments for severe asthma and chronic obstructive pulmonary disease, including albuterol (salbutamol), ipratropium bromide and an inhaled corticosteroid, and should start to roll out in the first half of 2005. Profile has already launched its first product, Promixin (colistimethate sodium) for cystic fibrosis, in the UK.

"Profile estimates the value of drugs in nebule form to be in excess of $1.0 billion (€883m) per annum and, through working with Breath, hopes to be able to secure a significant percentage of this market,"​ said the company.

Breath is the respiratory and sterile drug subsidiary of Arrow Group, a company set up by former Merck Generics chairman Tony Tabatznik to distribute and market generic drugs with subsidiaries in Europe, North America and Asia.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us


View more